GlassScriptPhysician profile
James Lewis
NPI 1053510586
$45,019.97
in general payments reported to CMS, 2019-2025
19 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $51.66 · 2022: $29.43 · 2023: $322 · 2024: $19K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $4,068 · Travel and Lodging: $3,515 · Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,301.35 |
| Consulting Fee | $4,068.00 |
| Travel and Lodging | $3,515.19 |
| Food and Beverage | $1,564.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43,952.85 | 2019-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $200.20 | 2019-2025 | Breyanzi |
| Davol INC. | $138.70 | 2025 | Arista |
| Merck Sharp & Dohme LLC | $136.26 | 2019-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $114.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $90.14 | 2023 | |
| Abbvie INC. | $79.39 | 2019-2020 | |
| Genentech USA, INC. | $64.49 | 2019-2024 | Perjeta, Phesgo |
| Boston Scientific Corporation | $50.98 | 2019 | |
| Teleflex LLC | $35.63 | 2025 | Quikclot |
| Caris Mpi, INC. | $23.00 | 2025 | Mi Cancer Seek |
| Ethicon US, LLC | $22.48 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Ethicon |
| Sun Pharmaceutical Industries INC. | $22.06 | 2019 | |
| Biocompatibles, INC. | $21.60 | 2019 | |
| Polynovo North America LLC | $19.27 | 2024 | Novosorb Btm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $18.60 | 2025 | Amtagvi |
| Kerecis Limited | $17.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Myriad Genetic Laboratories, INC. | $11.86 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.